CD25 ؉ CD4 ؉ FoxP3 ؉ regulatory T (Treg) cells isolated from the peripheral blood of asymptomatic HIV-infected individuals have been demonstrated to significantly suppress HIV-specific immune responses in vitro. CD25 ؉ Treg cell suppressor activity in the peripheral blood seems to diminish with progression of HIV disease, and it has been suggested that loss of Treg cells contributes to aberrant immune activation and disease progression. However, phenotypic studies suggest that Treg cells may migrate to, and be maintained or even expanded in, tissue sites of HIV replication. Currently, it is not known whether tissue-associated Treg cells maintain suppressive activity in the context of HIV infection, particularly in individuals with advanced disease. The present study demonstrates that CD25 ؉ Treg cells isolated from lymph nodes and peripheral blood of HIV ؉ subjects, even those with high viral loads and/or low CD4 ؉ T cell counts, maintain potent suppressive activity against HIV-specific cytolytic T cell function. This activity was better in lymph node as compared with peripheral blood, particularly in patients with high levels of plasma viremia. In addition, the expression of certain CD25 ؉ Treg-associated markers on CD4 ؉ T cells isolated from lymph nodes differed significantly from those on CD4 ؉ T cell subsets isolated from the peripheral blood. These data suggest that CD25 ؉ Treg cell-mediated suppression of HIV-specific responses continues throughout the course of HIV disease and, because of their particularly potent suppression of HIV-specific CTL activity in lymphoid tissue, may considerably impact the ability to control HIV replication in vivo.
cytolytic T lymphocyte ͉ cytokine ͉ proliferation U nder conditions of persistent antigen exposure and immune activation numerous immunosuppressive mechanisms function to limit potential immune-mediated damage to the host. Among the best characterized of these mechanisms are CD25 ϩ FoxP3 ϩ regulatory T (Treg) cells, a suppressor CD4 ϩ T cell subset initially described as playing a critical role in containing certain types of autoimmunity in animal models (1) . A potentially deleterious consequence of CD25 ϩ Treg cells is the suppression of appropriate antigen-specific immune responses. In this regard, CD25
ϩ Treg cells have been implicated in playing a role in disease/pathogen persistence, such as certain solid tumors and parasitic and bacterial infections (2) (3) (4) (5) (6) (7) (8) . Furthermore, CD25
ϩ Treg cells accumulate and expand at sites of antigen expression/ inflammation as well as in draining lymph nodes where they seem to exert particularly strong site-localized immunosuppression (2, 4, 9) .
Chronic HIV infection is characterized by loss of CD4 ϩ T cells, a broad array of immune dysfunctions, and persistent immune activation (10) (11) (12) . Whereas the direct and indirect roles of HIV and its gene products in immune dysfunction are well documented (13, 14) , recent evidence suggests that normal host-mediated negative immunoregulatory mechanisms, triggered by persistent antigenimia and immune activation, may also impact the immune competence of infected individuals (15) . In this regard, numerous in vitro studies have demonstrated that
CD25
ϩ Treg cells isolated from the peripheral blood of asymptomatic HIV-infected individuals significantly suppress HIVspecific CD4 ϩ and CD8 ϩ T cell immune responses (16) (17) (18) . However, progressive HIV disease has been associated with reduced frequencies or suppressor activity of CD25 ϩ Treg cells in the peripheral blood (PB) (17, (19) (20) (21) . These observations have led to the hypothesis that HIV infection is associated with a selective loss of CD25 ϩ CD4
ϩ Treg cells leading to a reduced ability to control HIV-associated aberrant immune activation and associated immune dysfunctions, ultimately resulting in more rapid disease progression. An alternative hypothesis is that CD25 ϩ Treg cells are redistributed to tissue sites of HIV expression (19, (22) (23) (24) . Currently, the data supporting this later. hypothesis is largely phenotypic and it is not known whether tissue-associated Treg cells, particularly in individuals with advanced disease, maintain their ability to suppress HIV-specific immune responses. Localization to and perhaps activation of CD25 ϩ Treg cells at lymphoid tissue sites might have a particularly negative impact on the ability of HIV-specific immune responses to control viral replication and spread. The present study investigates the suppressive activity of CD25 ϩ Treg cells isolated from lymph nodes (LN) and PB of chronically HIVinfected individuals at various stages of disease progression, including those with high viremia and/or CD4 ϩ T cells Ͻ150/l.
Results

Phenotypic Analyses of CD25 ؉ Treg Cells Isolated from Lymphoid
Tissue and Peripheral Blood. Total PB mononuclear cells (MC) and LNMC were stained for CD4, CD25, intracellular FoxP3 and additional putative CD25 ϩ Treg markers (CD127, SCTLA-4, or GITR). Previous studies with human PBMC have clearly correlated suppressor activity with a CD25 hi phenotype (25) and therefore, in the present study, CD25 ϩ Treg cells were identified by CD25 hi [mean fluorescence intensity (MFI) Ն 70] and FoxP3 (26, 27) coexpression (Fig. 1A) . The purity of the CD4 ϩ T cell subsets that were isolated on the basis of ϮCD25hi expression and subsequently added back to various cultures in functional assays (see below) is illustrated in Fig. 1B Functional Studies. In the present study, freshly isolated, matched PBMC and LNMC of chronically HIV-infected subjects 1-5 (see Table 1 ) were assessed for CD25 ϩ cell-mediated suppression of HIV-specific T cell function. Two of the study subjects had advanced disease (patients 1 and 5) with CD4 ϩ T cell counts/l of Ͻ150; patient 5 had a viral load (VL) of 58,791 copies/ml whereas patient 1 was on long-term antiretroviral therapy (ART), had a VL Ͻ50 copies/ml, and had Kaposi sarcoma. The remaining patients had CD4
ϩ T cell counts of Ͼ350 and variable VL (Ͻ50-203,495 copies per ml). CD25
ϩ Treg activity was assessed by comparing HIV-specific T cell function in unfractionated versus CD25 ϩ cell-depleted MC, unless otherwise indicated.
Lymphoproliferation Assay. The most common method to assess CD25 ϩ Treg suppressor activity has been to demonstrate inhibition of normal CD25 Ϫ CD4 ϩ T cell proliferation. Using such functional assays, we previously reported on the difficulty in detecting suppressive activity of PB-derived CD25 ϩ Treg cells isolated from chronically HIV-infected individuals with advanced disease compared with HIV ϩ subjects with a favorable clinical status (17) . In the present study, total and CD25 ϩhi cell-depleted CD4 ϩ T cells (see Fig. 1B ) isolated from PBMC and LNMC of patients 1-5 (Table 1) were compared for proliferation in response to HIV p24. As expected, CD4 ϩ T cells from the two individuals with advanced disease (subjects 1 and 5) failed either to proliferate to HIV p24 or failed to exert CD25ϩ cell-mediated suppression (Ն 40% inhibition) (Fig. 4) . Although subject 1 had been on ART and had an undetectable viral load for some time, both these individuals had Ͻ150 CD4 ϩ T cells per l, suggesting that CD4 ϩ T cell count was most relevant to Treg activity in this assay. As reported (17) , in vitro
CD25
ϩ Treg activity was most potent within both PBMC and LNMC of the individual (subject 2) with the best clinical status (CD4 ϩ T cells Ͼ500/l and VL Ͻ50) (Fig. 4) . The effect of CD25 ϩhi cell depletion on allogeneic antigen-induced proliferation in LNMC and PBMC is shown in SI Fig. 8 .
Assays of Cytolytic Activity. As HIV-specific proliferation assays proved to be problematic for the assessment of CD25ϩ Treg activity, we sought to measure CD25ϩ Treg suppressor capacity using another relevant functional assay. Virus-specific CD8 ϩ T cell-mediated cytolytic (CTL) activity is thought to be critical in the control or elimination of most viral infections, including HIV (30) (31) (32) (33) (34) . As the lymphoid tissue is the major site of active HIV replication (35) (36) (37) , HIV-specific CTL activity in the lymph nodes likely represents an important immunologic response with regard to control of HIV replication in vivo. In the present study we compared unfractionated and CD25 ϩhi cell-depleted PBMC and LNMC from patients 1-5 for HIV-specific cytolytic activity (Granzyme B substrate cleavage) in HIV Gag peptide restimulation assays. In addition, with cells from patients 3-5, we were able to assess relative Treg suppressive activity in CD25 Ϫ MC plus CD25 ϩhi versus CD25
Ϫ CD4 ϩ T cell add-back experiments. As seen in a representative experiment (Fig. 5) , HIV Gagspecific target cell ''killing'' was enhanced in CD25 ϩ celldepleted (Middle plots) compared with unfractionated (Top plots) LNMC and was dramatically suppressed by the readdition of 30% CD25 hiϩ CD8
Ϫ (Ն85% CD4 ϩ T cells; data not shown) ART, antiretroviral therapy; Tc, T cells . *VL measured using assays with a limit of detection of 10,000 HIV RNA copies per ml. 
Fig. 4. CD25ϩ
Treg suppressive capacity assessed in HIV p24-specific proliferation assays. Total and CD25 ϩ cell-depleted CD4 ϩ T cells isolated from LNMC and PBMC of subjects 1-5 were stimulated with HIV p24 protein for 6 days, then pulsed with 3 H thymidine 16 h. Percent suppression of proliferation by CD25 ϩ cells was determined by comparing net cpm obtained in total versus CD25 ϩ cell-depleted CD4 ϩ T cell cultures (Ն40% was arbitrarily considered to be a significant level of suppression). N.R., no response.
LNMC to CD25
ϩ cell-depleted LNMC (Bottom Right plot). HIV-specific CTL activity was detected in both PBMC and LNMC of all study subjects and, comparing unfractionated versus CD25 ϩ cell-depleted MC, significant CD25 ϩ cellmediated suppression of HIV-specific CTL activity was observed with both PBMC and LNMC (Fig. 6A) . Of interest, a difference in the ability of LN CD25ϩ Tregs to suppress HIV-specific CTL activity was seen between patients with high, compared with patients with low, levels of viremia. In this regard, CD25 ϩ cell-mediated suppression of HIV-specific CTL activity in LNMC of the two subjects with the highest VL (VL Ͼ50,000; patients 4 and 5) was significantly greater than that observed in LNMC of subjects with VL Ͻ25,000 HIV RNA copies/ml (Fig.  6B) . This difference in CD25 ϩ Treg activity related to level of viremia was not significant with PBMC (Fig. 6B) . To determine whether CD25
ϩ Treg cells isolated from the PB and LN differed in regard to their suppressive capability, LN or PB-derived CD25 hiϩ or CD25 Ϫ CD4 ϩ T cells were added back (at 10%) to CD25 Ϫ MC effector populations at the time of initial HIV Gag peptide stimulation. Both PB and LN-derived CD25
hiϩ , but not CD25 Ϫ , CD4 ϩ T cells suppressed HIV-specific CTL activity (Fig. 6C) ; however, the suppressive effect of LN-derived CD25 hiϩ CD4 ϩ T cells was significantly greater than that observed with PB-derived CD25 hiϩ CD4 ϩ T cells (Fig. 6C) .
Discussion
The present study was designed to determine the functional capability of lymphoid tissue-derived CD25 ϩ Treg cells, particularly those isolated from individuals with advanced HIV disease, with regard to their suppressive effects on HIV-specific T cell responses. The answer to this question is critical to determining whether immunosuppressive CD25 ϩ Treg cells represent a reasonable target for immune-based approaches for enhancing HIV-specific immune responses and, if so, whether such an approach is appropriate at all stages of HIV disease. The results of this study indicate that CD25
ϩ Treg cells maintain significant suppressive activity against HIV-specific cytolytic T cell responses even in the advanced stage of HIV disease. Furthermore, LN-derived CD25 ϩ Treg cells suppressed HIV-specific responses to a greater degree than did PB-derived CD25
ϩ Treg cells, particularly in those individuals with high viral loads.
Natural CD25 hi FoxP3 ϩ Treg cells are an important component of the immune surveillance system designed to control autoimmunity (1); however, their suppressive activity has been shown to also impact appropriate foreign antigen-specific immune responses. In this regard, CD25 ϩ Treg cell activity has been shown to contribute to the persistence of certain infections and tumors in vivo (2) (3) (4) (5) (6) (7) (8) . In addition, suppressive antigen-specific CD25
ϩ Treg cells can be generated (''induced'' CD25 ϩ Treg cells) from presumably normal 
CD4
ϩ T cells under certain pathogenic/micro environmental conditions (38, 39) . Whether natural or induced, CD25
ϩ Treg cells have been demonstrated to accumulate and expand at tissue sites of inflammation/antigen expression where cell contact-mediated suppression may be particularly effective (2, 4, 9) . In HIV disease, HIV replication/antigen expression largely occurs in the lymphoid tissue (36, 37) , the site at which primary immune responses to most antigens are generated. Therefore, antigen-driven accumulation and activation of CD25 ϩ Treg cells in lymphoid tissue sites could have a considerable impact not only on effector cell function but also on the generation of lymphocyte responses to new antigens or antigenic epitopes, as might arise in the case of highly mutable HIV.
Results from early studies using PB suggested that CD25
ϩ FoxP3 ϩ Treg cell function and/or frequency decline with HIV disease progression (17, (19) (20) (21) . Evidence that CD25
ϩ Treg cells are not necessarily lost over the course of HIV disease but rather accumulate in the lymphoid tissue has been generated by in situ phenotypic and mRNA studies (19, 22, 24) . High levels of HIV replication have been associated with the accumulation of cells with a Treg-like phenotype and/or FoxP3, TGF-␤ and IDO mRNA in tonsils (19, 24) and lamina propria (22) . In our phenotypic studies, CD25
hi FoxP3 ϩ cell frequencies in LNMC were consistently higher than in PBMC regardless of viral load or CD4 ϩ T cell counts of the study subject. In contrast, the frequency of CD25 ϩhi Treg cells is reported to be similar in lymph node and PB of healthy HIV uninfected controls (40) . Of interest, we also observed that FoxP3 intensity (MFI) in the CD25 ϩ CD4
ϩ T cell subset of LNMC was significantly higher than that in PBMC. It has been reported that human CD25 ϩ Treg cells expressing high levels of FoxP3 exhibit more rapid suppressive activity compared with FoxP3 mid CD25
ϩ Treg cells (41) . With regard to additional surface markers associated with CD25 ϩ Treg cells, CD25
hi FoxP3 ϩ CD4 ϩ T cells exhibited higher GITR expression in the LN than in PB, which suggests that LN Treg cells would be more likely to be activated and expand in response to interaction with dendritic cells that express GITR-L (42, 43) . CD127 neg/lo (29) was the most specific surface phenotype for CD25 hi FoxP3 ϩ CD4 ϩ T cells in both PB and LN; however, a greater proportion of CD25 hi FoxP3 ϩ Treg cells expressed CD127 hi , rather than CD127 neg/lo , in the LN compared with the PB. Overall , no surface marker was sufficient to fully and accurately discriminate between CD25 hi FoxP3 ϩ Treg cells and normal CD4 ϩ T cells in the LN.
Importantly, our functional studies demonstrate that CD25 ϩ Treg cells isolated from both the PB and LN of all subjects, even those with advanced disease, retain significant suppressive activity as detected by HIV-specific CTL assays. Although the sample size in the present study was low, the data suggest that CD25 ϩ Treg cell-mediated suppression of HIV-specific CTL activity is more effective in lymphoid tissue than in PB, particularly in those patients with moderate/high compared with undetectable/low viral loads. Whereas in vitro human CD25ϩ Treg cells have generally been found to suppress CD4 ϩ T cell proliferation via an ill-defined cell contact-dependent, IL-10/ transforming growth factor (TGF)-␤-independent mechanism (44), in vivo CD25 ϩ Treg cells are thought to exert immunosuppression by numerous mechanisms, including TGF-␤ (28, 45, 46) . Increased CD25 ϩ Treg activity in LNMC compared with PBMC may be due to differences in the frequency of CD25 ϩ Treg cell subsets that suppress by the production or induction of soluble immunosuppressive factors (47, 48) , particularly TGF-␤. Although definitive comparative studies of TGF-␤ production by PBMC and LNMC in chronically HIV-infected individuals have not been performed, TGF-␤ is elevated in the lymphoid tissue of viremic HIV-infected subjects (19, 22, 24) . Of note, Tregmediated suppression of antigen-specific CTL activity in certain murine models has been shown to be TGF-␤-dependent (49, 50).
Using proliferation assays as a read-out, we previously reported on a cohort of patients that exhibited a loss of CD25 ϩ Treg suppressive activity against HIV-specific CD4 ϩ T cell responses in the PB with HIV disease progression (17) . We proposed, as have others (19) , that ''HIV-specific'' Treg cells might migrate out of the blood into the lymph nodes during periods of viremia and we hypothesized that CD25
ϩ Treg activity against HIV-specific T cell function would be retained in lymphoid tissue. However, in the present study, CD25
ϩ cellmediated suppression of HIV-specific CD4 ϩ T cell proliferation was not observed in either PBMC or LNMC isolated from individuals with more advanced disease, although suppression of HIV-specific CTL activity was detected in both PBMC and LNMC of all subjects. The apparent differential sensitivity of antigen-specific proliferation and cytotoxicity to CD25ϩ Tregmediated suppression has not been reported in the context of HIV infection. It is possible that factors that reduce sensitivity of normal T cells to CD25
ϩ Treg-mediated suppression, such as TCR signal strength, GITR expression and IL-6, (28, 43, 51-53)} differ in the two assay systems. Alternatively, different CD25ϩ Treg subsets (47) or mechanisms (45, 46) may suppress CTL effector function more efficiently than other T cell functions. In this regard, there is evidence in murine models indicating that CD25ϩTreg-mediated suppression of CD8ϩ effector functions, but not of T cell proliferation, requires intact TGF-␤ signaling (45, 50, 54) . Furthermore, it has been suggested that cytolytic activity may be the most Treg-sensitive T cell function in vivo (49) . The data from the present study would suggest that CTL activity in humans is also more sensitive to CD25
ϩ Tregmediated suppression than is proliferation or other effector functions, at least in the context of progressive HIV disease.
In summary, the present study provides proof of concept that CD25
ϩ Treg cells maintain the ability to suppress HIV-specific responses, particularly CTL function, throughout the course of HIV disease. CD25ϩ Treg-mediated suppression of HIVspecific cytolytic activity in lymphoid tissue, the major site of HIV replication, may be particularly detrimental to the ability to control virus replication in vivo. It remains to be established whether immune-based therapies designed to transiently deplete CD25 ϩ Treg cells in vivo would ultimately be beneficial or detrimental in the context of HIV infection.
Materials and Methods
Cellular Subset Isolation. Inguinal or axillary LN biopsies and lymphophereses were obtained after informed consent from 11 HIV-infected individuals under National Institutes of Health (NIH) approved protocols (NIH 92-I-25, 02-I-0202, and 81-I-0164). The clinical profiles of study subjects are shown in Table  1 . Fresh LNMC and PBMC of individuals 1-5 were used in functional assays and frozen LNMC and PBMC from subjects 6-11 were used for phenotypic studies only. LNMC were obtained by gentle physical disruption (scalpel microdissection) and collagenase treatment. PBMC were isolated by centrifuge density gradient. MCs or CD4 ϩ T cells [isolated by using a negative selection antibody mixture and immunomagnetic beads (Stem Cell Technologies, Vancouver, BC, Canada)] were retained as unfractionated or separated into CD25 ϩhi and CD25 Ϫ subsets. CD25 hi cells were obtained by using anti-human CD25 PE conjugated Mab (3 l/10 6 cells) followed by a short incubation (3 min) with anti-PE immunomagnetic beads (Miltenyi, Auburn, CA). For certain assays, the CD25 Ϫ MC were further depleted of CD8 ϩ cells by using anti-CD8-coupled immunomagnetic beads (Dynal, Brown Deer, WI) to derive CD8 Ϫ CD25 Ϫ control MC (Ն85% CD4 ϩ T cells). CD25 ϩ Treg phenotypic analyses were performed on total LNMC and PBMC by using anti-human FoxP3 (intracellular; EBiosciences, San Diego, CA), CD4, CD25, CD127, CTLA-4 and GITR. All antibodies were
